273 related articles for article (PubMed ID: 27029827)
1. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
2. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
4. KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells.
Beretta GL; Alampi D; Corno C; Carenini N; Corna E; Perego P
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732265
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
7. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
[TBL] [Abstract][Full Text] [Related]
8. Paired box 5 is a frequently methylated lung cancer tumour suppressor gene interfering β-catenin signalling and GADD45G expression.
Zhao L; Li S; Gan L; Li C; Qiu Z; Feng Y; Li J; Li L; Li C; Peng W; Xu C; Wang Z; Hui T; Ren G; Tao Q; Xiang T
J Cell Mol Med; 2016 May; 20(5):842-54. PubMed ID: 26843424
[TBL] [Abstract][Full Text] [Related]
9. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Hurtubise A; Momparler RL
Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
[TBL] [Abstract][Full Text] [Related]
10. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.
Tang X; Yin X; Xiang T; Li H; Li F; Chen L; Ren G
Cancer Biomark; 2012-2013; 12(1):11-9. PubMed ID: 23321465
[TBL] [Abstract][Full Text] [Related]
11. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
12. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
13. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
14. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Huang L; Sowa Y; Sakai T; Pardee AB
Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
[TBL] [Abstract][Full Text] [Related]
15. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
16. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
[TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
[TBL] [Abstract][Full Text] [Related]
19. Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers.
Palmisano WA; Crume KP; Grimes MJ; Winters SA; Toyota M; Esteller M; Joste N; Baylin SB; Belinsky SA
Cancer Res; 2003 Aug; 63(15):4620-5. PubMed ID: 12907641
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers.
Drzewiecka H; Gałęcki B; Jarmołowska-Jurczyszyn D; Kluk A; Dyszkiewicz W; Jagodziński PP
J Cancer Res Clin Oncol; 2016 Sep; 142(9):1927-46. PubMed ID: 27393180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
